Humacyte, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 110.78 million compared to USD 11.97 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 0.12 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.42 USD | -0.77% | +42.04% | +126.06% |
May. 10 | Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
Mar. 28 | Transcript : Humacyte, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+126.06% | 765M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.11% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023